Fluocinolone ophthalmic Pregnancy and Breastfeeding Warnings
Medically reviewed by Drugs.com. Last updated on Oct 6, 2022.
Fluocinolone ophthalmic is also known as: Iluvien, Retisert, Yutiq
Fluocinolone ophthalmic Pregnancy Warnings
Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Use should be avoided.
US FDA pregnancy category: C
Fluocinolone ophthalmic Breastfeeding Warnings
A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comments:
-The effects in the nursing infant are unknown.
-Systemic steroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects.
See also
References for pregnancy information
- "Product Information. Retisert (fluocinolone ophthalmic)." Bausch and Lomb Americas, Inc. (2005):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
References for breastfeeding information
- "Product Information. Retisert (fluocinolone ophthalmic)." Bausch and Lomb Americas, Inc. (2005):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.